STAT News' Pharmalot newsletter reported Wednesday-Thursday July 8-9, 2026 that the White House is reviewing three finalists to lead the FDA following the departure of the prior commissioner earlier in 2026: Heidi Overton, a policy adviser in the White House itself; Jeffrey Vacirca, an oncologist and health-system executive; and Stephen Ferrara, a health official at the Department of Defense. Axios first surfaced the shortlist on June 26; the July 8-9 STAT reporting confirmed the trio is under active White House review with a decision expected in the coming weeks. The peptide policy trajectory tracks through whichever nominee advances. FDA career-staff briefing documents released June 29-30 concluded all seven PCAC peptides have insufficient evidence for 503A eligibility, while HHS Secretary RFK Jr.'s public push points the other direction; the incoming commissioner will inherit an agency-vs-secretary tension around peptide compounding as the July 23-24 PCAC vote lands. The nominee will also inherit the pending Novo Nordisk-Vivani semaglutide-implant evaluation agreement, the Sandoz generic-tirzepatide ANDA acceptance from June 29, and the ongoing 503B GLP-1 exclusion rulemaking.
California Rep. Ted Lieu (D) held a press conference on June 24, 2026 suggesting that President Trump canceled the signing of the bipartisan 21st Century ROAD to Housing bill earlier that day because he is fighting a terminal illness and dealing with side effects from an experimental drug. Lieu pointed to the STAT News retatrutide compassionate-use report and reasoned that compassionate-use access typically requires terminal illness. Lieu cited Trump being 'unable to stay awake at meetings, having visible arm weakness, and swelling in his hands' as supporting observations. White House Communications Director Steven Cheung responded by calling Lieu a 'dumba--' for the suggestion. The exchange escalated the political dimension of the retatrutide story from White House versus reporter (Kush Desai vs Lizzy Lawrence on June 23-24) to House Democrat versus White House Communications Director. The 21st Century ROAD to Housing Act is a bipartisan housing reform bill that Trump was scheduled to sign on Wednesday June 24, 2026, with the signing canceled the same day. The White House has not provided a public explanation for the cancellation beyond denying any connection to the retatrutide story.
Following STAT News reporter Lizzy Lawrence's June 23 scoop that the FDA and Eli Lilly granted compassionate-use retatrutide access to a 79-year-old patient on the application of NIH senior clinician Dr. Ranganath Muniyappa, the White House response intensified June 23-24. Senior deputy press secretary Kush Desai posted on X that 'this application was not for the President' but did not explicitly deny that Trump (who turned 80 on June 14) had separately applied. After Lawrence reported the non-denial, Desai publicly called her 'an unserious gossip columnist.' The White House rapid response team added: 'No, it wasn't President Trump — and you people are truly sick and deranged.' The escalation moves the story from a closed regulatory-access question to an active political controversy, with outlets including The Hill, IBTimes UK, Slate, MS NOW, Hello Magazine, Tech Times, and The New Republic running parallel coverage. Outside medical experts continue to question whether refractory obesity plus OSA plus pulmonary hypertension meets the FDA's compassionate-use threshold typically reserved for immediately life-threatening illness.